Skip to main content
. Author manuscript; available in PMC: 2011 Nov 17.
Published in final edited form as: Clin Cancer Res. 2009 Aug 11;15(16):5267–5273. doi: 10.1158/1078-0432.CCR-09-0888

Fig. 1.

Fig. 1

A, OS in patients with exon 19 deletions versus L858R point mutations. B, OS based on EGFR and KRAS status.